Polatuzumab Vedotin
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB12240 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 32 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | HER2 positive breast carcinoma | KG + DL |
| 2 | progesterone-receptor positive breast cancer | KG + DL |
| 3 | normal breast-like subtype of breast carcinoma | KG + DL |
| 4 | breast tumor luminal A or B | KG + DL |
| 5 | progesterone-receptor negative breast cancer | KG + DL |
| 6 | drug-induced osteoporosis | KG + DL |
| 7 | acne (disease) | KG + DL |
| 8 | antithrombin deficiency type 2 | KG + DL |
| 9 | heparin cofactor 2 deficiency | KG + DL |
| 10 | factor 5 excess with spontaneous thrombosis | KG + DL |
| 11 | severe nonproliferative diabetic retinopathy | KG + DL |
| 12 | thrombophilia | KG + DL |
| 13 | amenorrhea (disease) | KG + DL |
| 14 | zinc, elevated plasma | KG + DL |
| 15 | infectious bovine rhinotracheitis | KG + DL |
| 16 | malignant catarrh | KG + DL |
| 17 | primary release disorder of platelets | KG + DL |
| 18 | kidney pelvis sarcomatoid transitional cell carcinoma | KG + DL |
| 19 | prostatic urethra urothelial carcinoma | KG + DL |
| 20 | infiltrating bladder urothelial carcinoma sarcomatoid variant | KG + DL |
| 21 | renal pelvis papillary urothelial carcinoma | KG + DL |
| 22 | cytomegalovirus infection | KG + DL |
| 23 | pseudo-von Willebrand disease | KG + DL |
| 24 | transitional cell carcinoma | KG + DL |
| 25 | diabetic retinopathy | KG + DL |
| 26 | Richter syndrome | KG + DL |
| 27 | Glanzmann thrombasthenia | KG + DL |
| 28 | metastatic neoplasm | KG + DL |
| 29 | malignant spiradenoma | KG + DL |
| 30 | migraine with brainstem aura | KG + DL |
| 31 | hidradenitis | KG + DL |
| 32 | migraine disorder | KG + DL |
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.